What is William Blair’s Forecast for TLX FY2027 Earnings?

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) – William Blair dropped their FY2027 earnings estimates for shares of Telix Pharmaceuticals Limited American Depositary Shares in a report released on Wednesday, March 12th. William Blair analyst A. Hsieh now expects that the company will post earnings per share of $1.44 for the year, down from their prior estimate of $1.46. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares’ current full-year earnings is $0.24 per share.

Separately, UBS Group increased their target price on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Price Performance

TLX stock opened at $17.30 on Thursday. Telix Pharmaceuticals Limited American Depositary Shares has a 12-month low of $14.01 and a 12-month high of $30.36. The business has a 50 day moving average of $17.47.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.